BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12923388)

  • 1. Endothelial COX-2 inhibition: possible relevance for hypertension and cardiovascular risk?
    Stiller CO; Hjemdahl P
    J Hypertens; 2003 Sep; 21(9):1615-8. PubMed ID: 12923388
    [No Abstract]   [Full Text] [Related]  

  • 2. COX-2 and COX-2 enzyme inhibition.
    Conti P
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):I-II. PubMed ID: 14552697
    [No Abstract]   [Full Text] [Related]  

  • 3. COX-2 inhibitors cut risk of colon polyps.
    Health News; 2000 Aug; 6(8):6. PubMed ID: 10948872
    [No Abstract]   [Full Text] [Related]  

  • 4. Cyclooxygenase 2 inhibitors.
    Kelley KW; Ramsey LA
    Adv Nurse Pract; 2003 Mar; 11(3):22-4. PubMed ID: 12683165
    [No Abstract]   [Full Text] [Related]  

  • 5. [Assessing the coxibs].
    Paakkari I
    Duodecim; 2003; 119(21):2071-7. PubMed ID: 14655538
    [No Abstract]   [Full Text] [Related]  

  • 6. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
    Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
    Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute interstitial nephritis and COX-2 inhibition.
    Chow KM; Szeto CC; Li P; Lai FM
    Hosp Med; 2003 Jul; 64(7):429. PubMed ID: 12886856
    [No Abstract]   [Full Text] [Related]  

  • 8. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
    Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F
    Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Specific cyclo-oxygenase-2 inhibitors in cardiovascular pathology].
    Monsuez JJ
    Arch Mal Coeur Vaiss; 2004 Jun; 97(6):632-40. PubMed ID: 15283037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.
    Howard PA; Delafontaine P
    J Am Coll Cardiol; 2004 Feb; 43(4):519-25. PubMed ID: 14975457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cardiovascular ffects of COX-2 selective anti-inflammatory agents].
    Halinen MO
    Duodecim; 2001; 117(24):2570-1. PubMed ID: 12183817
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells.
    Niederberger E; Manderscheid C; Grösch S; Schmidt H; Ehnert C; Geisslinger G
    Biochem Pharmacol; 2004 Jul; 68(2):341-50. PubMed ID: 15194006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COX-2 inhibitors in the treatment of cardiovascular disease.
    Raynauld JP
    CMAJ; 2002 Oct; 167(7):739; author reply 739-40. PubMed ID: 12389825
    [No Abstract]   [Full Text] [Related]  

  • 14. COX-2 inhibitors in the treatment of cardiovascular disease.
    Peterson JC
    CMAJ; 2002 Oct; 167(7):738-9; author reply 739-40. PubMed ID: 12389824
    [No Abstract]   [Full Text] [Related]  

  • 15. Concluding remarks. C0X-2-selective inhibition: a new advance in pain management.
    Korttila K
    Eur J Anaesthesiol Suppl; 2002; 25():21-3. PubMed ID: 12596801
    [No Abstract]   [Full Text] [Related]  

  • 16. Is there anything else we could possibly need to know about COX-2 selective inhibitor drugs?
    Davis P; Juby A; Robertson S; Richard N
    J Rheumatol; 2004 May; 31(5):847-8. PubMed ID: 15124241
    [No Abstract]   [Full Text] [Related]  

  • 17. Cyclooxygenase inhibition in patients with coronary artery disease.
    Frishman WH
    J Am Coll Cardiol; 2004 Feb; 43(4):532-3. PubMed ID: 14975459
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
    Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
    Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential danger of COX-2 inhibitors.
    Norman RJ; Wu R
    Fertil Steril; 2004 Mar; 81(3):493-4. PubMed ID: 15037388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Means, responders, and meaning: evaluation of clinical trials in osteoarthritis.
    Schnitzer TJ
    Arthritis Rheum; 2003 Nov; 48(11):3001-3. PubMed ID: 14613258
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.